摘要：SummaryMetabolic reprogramming in cancer cells can create metabolic liabilities.KEAP1-mutant lung cancer is refractory to most current therapies. Here we show thatKEAP1deficiency promotes glucose dependency in lung cancer cells, andKEAP1-mutant/deficient lung cancer cells are more vulnerable to glucose deprivation than their WT counterparts. Mechanistically,KEAP1inactivation in lung cancer cells induces constitutive activation of NRF2 transcription factor and aberrant expression of NRF2 target cystine transporter SLC7A11; under glucose limitation, high cystine uptake inKEAP1-inactivated lung cancer cells stimulates toxic intracellular disulfide buildup, NADPH depletion, and cell death, which can be rescued by genetic ablation of NRF2-SLC7A11 axis or treatments inhibiting disulfide accumulation. Finally, we show thatKEAP1-inactivated lung cancer cells or xenograft tumors are sensitive to glucose transporter inhibitor. Together, our results reveal thatKEAP1deficiency induces glucose dependency in lung cancer cells and uncover a therapeutically relevant metabolic liability.Graphical abstractDisplay OmittedHighlights•Mutant KEAP1 exposes a metabolic liability provoked by high cystine uptake•KEAP1-NRF2-SLC7A11 axis drives glucose dependency•KEAP1 mutant NSCLC tumors are sensitive to GLUT inhibitorPhysiology; Cell biology; Cancer
